Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Royalty Pharma plcRPRX · Entity 3100 | EVP, Investments & CLO | December 17, 2025 | December 19, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Royalty Pharma plc
Report date December 17, 2025 · Filed December 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectBy GWL 2014 G, LLC | 30,654 |
Reported balance
After 2025-12-17 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-12-17 · Sale · Disposed 79,346 · Balance 30,654 F1: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.31 to $38.87 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectBy GWL 2014 G, LLC | 0 |
Reported balance
After 2025-12-18 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-12-18 · Sale · Disposed 30,654 · Balance 0 F1: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025. F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.31 to $38.67 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectBy GWL 2013 NG, LLC | 495,860 |
Reported balance
Holding disclosure · report date 2025-12-17 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 495,860 |
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectBy IRA | 273,960 |
Reported balance
Holding disclosure · report date 2025-12-17 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 273,960 |
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectBy GWL 2023 G HoldCo LLC | 6,084 |
Reported balance
Holding disclosure · report date 2025-12-17 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 6,084 |
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectBy Spouse | 4,011.19 |
Reported balance
Holding disclosure · report date 2025-12-17 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 4,011.19 |
Filing footnotes · ownership attribution and instrument terms
F1: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.31 to $38.87 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.31 to $38.67 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 31, 2020 Filed Jan 5, 2021 21:43 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionClass A Ordinary Shares | 400,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-000104 · dp143909_4-lloyd.xml · nonDerivative · entry 2 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 400,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value was paid by the Reporting Person in connection with the exchange. F1 · price: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value was paid by the Reporting Person in connection with the exchange. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 21:43 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionClass A Ordinary Shares | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-000104 · dp143909_4-lloyd.xml · nonDerivative · entry 1 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2013 NG, LLC Disclosed balance after: 100,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value was paid by the Reporting Person in connection with the exchange. F1 · price: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value was paid by the Reporting Person in connection with the exchange. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 21:54 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionLP interests in RPI International Holdings 2019, LP · Derivative | 26,276 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950103-20-012148 · dp130794_4-lloyd.xml · derivative · entry 9 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA Disclosed balance after: 2,050 Underlying: Class A Ordinary Shares · 262,760 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP ("RPI Intl. LP"). Each limited partnership interest in RPI Intl. LP ("RPI Intl. LP Interest") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, ("Holdings"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value was paid by the Reporting Person in connection with the exchange. F1 · kind: These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP ("RPI Intl. LP"). Each limited partnership interest in RPI Intl. LP ("RPI Intl. LP Interest") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, ("Holdings"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value was paid by the Reporting Person in connection with the exchange. F2 · kind: This exchange was effected by the General Partner of RPI Intl. LP in accordance with a provision of the Limited Partnership Agreement of RPI Intl. LP applicable in the event of the public offering of the Issuer's Class A Ordinary Shares. The exchange applied to all holders of RPI Intl. LP Interests that did not opt out of participation. F8 · derivative.exercise_date: Represents limited partnership interests in RPI Intl. LP Interests. Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F8 · derivative.expiration_date: Represents limited partnership interests in RPI Intl. LP Interests. Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F9 · balance_after: Includes RPI Intl. LP Interests convertible into 20,500 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 21:54 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionClass A Ordinary Shares | 262,760 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-20-012148 · dp130794_4-lloyd.xml · nonDerivative · entry 3 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA Disclosed balance after: 273,960 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP ("RPI Intl. LP"). Each limited partnership interest in RPI Intl. LP ("RPI Intl. LP Interest") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, ("Holdings"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value was paid by the Reporting Person in connection with the exchange. F2 · kind: This exchange was effected by the General Partner of RPI Intl. LP in accordance with a provision of the Limited Partnership Agreement of RPI Intl. LP applicable in the event of the public offering of the Issuer's Class A Ordinary Shares. The exchange applied to all holders of RPI Intl. LP Interests that did not opt out of participation. F1 · price: These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP ("RPI Intl. LP"). Each limited partnership interest in RPI Intl. LP ("RPI Intl. LP Interest") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, ("Holdings"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value was paid by the Reporting Person in connection with the exchange. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 21:54 UTC | Royalty Pharma plc RPRX · Entity 3100 | PurchaseClass A Ordinary Shares | 11,200 | $28.00 | $313,600.00 |
DisclosureSEC source: 0000950103-20-012148 · dp130794_4-lloyd.xml · nonDerivative · entry 2 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA Disclosed balance after: 11,200 Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 21:54 UTC | Royalty Pharma plc RPRX · Entity 3100 | PurchaseClass A Ordinary Shares | 3,000 | $28.00 | $84,000.00 |
DisclosureSEC source: 0000950103-20-012148 · dp130794_4-lloyd.xml · nonDerivative · entry 1 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Read SEC document |
| June 15, 2020 Filed Jun 22, 2020 21:54 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantICAI Interests · Derivative | 353,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950103-20-012148 · dp130794_4-lloyd.xml · derivative · entry 8 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 353,000 Underlying: Limited Partnership interests in RPI US Partners 2019, LP · 353,000 shares Expires not disclosed F3 · kind: The Reporting Person acquired beneficial ownership of Class B Interests in Holdings and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP ("RPI US LP") and RPI Intl. LP for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020. F10 · derivative.exercise_date: These ICAI Interests represent a grant of up to 353,000 RPI US LP Interests. These ICAI Interests expire on December 15, 2023, and are subject to four-year vesting, with 25% of the interests vesting on February 12, 2021 and the remainder vesting in 36 equal monthly installments thereafter. Subject to these vesting requirements, the full number of RPI US LP Interests is issuable in respect of these ICAI Interests if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The number of RPI US LP Interests issuable in respect of these ICAI Interests scales linearly from 0% at $20.51 per share to 100% at $32.30 per share. F10 · derivative.expiration_date: These ICAI Interests represent a grant of up to 353,000 RPI US LP Interests. These ICAI Interests expire on December 15, 2023, and are subject to four-year vesting, with 25% of the interests vesting on February 12, 2021 and the remainder vesting in 36 equal monthly installments thereafter. Subject to these vesting requirements, the full number of RPI US LP Interests is issuable in respect of these ICAI Interests if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The number of RPI US LP Interests issuable in respect of these ICAI Interests scales linearly from 0% at $20.51 per share to 100% at $32.30 per share. F4 · derivative.underlying: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. Read SEC document |
| June 15, 2020 Filed Jun 22, 2020 21:54 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantLP interests in RPI International Holdings 2019, LP · Derivative | 28,326 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950103-20-012148 · dp130794_4-lloyd.xml · derivative · entry 7 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA Disclosed balance after: 28,326 Underlying: Class A Ordinary Shares · 283,260 shares Expires not disclosed F3 · kind: The Reporting Person acquired beneficial ownership of Class B Interests in Holdings and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP ("RPI US LP") and RPI Intl. LP for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020. F8 · derivative.exercise_date: Represents limited partnership interests in RPI Intl. LP Interests. Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F8 · derivative.expiration_date: Represents limited partnership interests in RPI Intl. LP Interests. Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F9 · balance_after: Includes RPI Intl. LP Interests convertible into 20,500 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share. Read SEC document |
| June 15, 2020 Filed Jun 22, 2020 21:54 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantLP interests in RPI US Partners 2019, LP · Derivative | 596,707 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950103-20-012148 · dp130794_4-lloyd.xml · derivative · entry 6 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2014 G, LLC Disclosed balance after: 596,707 Underlying: Class A Ordinary Shares · 5,967,070 shares Expires not disclosed F3 · kind: The Reporting Person acquired beneficial ownership of Class B Interests in Holdings and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP ("RPI US LP") and RPI Intl. LP for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020. F4 · derivative.exercise_date: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F4 · derivative.expiration_date: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F7 · balance_after: Includes RPI US LP Interests convertible into 4,573,096 Class A Ordinary Shares that are subject to an agreement by and between the reporting person and RP Management, LLC under which the reporting person has agreed to retain and not sell such interests before February 2025. This restriction is waivable under certain circumstances. Read SEC document |
| June 15, 2020 Filed Jun 22, 2020 21:54 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantLP interests in RPI US Partners 2019, LP · Derivative | 83,638 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950103-20-012148 · dp130794_4-lloyd.xml · derivative · entry 5 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Indirect · By GWL 2013 NG, LLC Disclosed balance after: 83,638 Underlying: Class A Ordinary Shares · 836,380 shares Expires not disclosed F3 · kind: The Reporting Person acquired beneficial ownership of Class B Interests in Holdings and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP ("RPI US LP") and RPI Intl. LP for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020. F4 · derivative.exercise_date: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F4 · derivative.expiration_date: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F6 · balance_after: Includes RPI US LP Interests convertible into 60,520 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share. Read SEC document |
| June 15, 2020 Filed Jun 22, 2020 21:54 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantLP interests in RPI US Partners 2019, LP · Derivative | 7,730 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950103-20-012148 · dp130794_4-lloyd.xml · derivative · entry 4 Lloyd George W. · CIK 0001814899 · EVP, Investments & GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,730 Underlying: Class A Ordinary Shares · 77,300 shares Expires not disclosed F3 · kind: The Reporting Person acquired beneficial ownership of Class B Interests in Holdings and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP ("RPI US LP") and RPI Intl. LP for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020. F4 · derivative.exercise_date: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F4 · derivative.expiration_date: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F5 · balance_after: Includes RPI US LP Interests convertible into 5,590 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.